Keith T. Flaherty

121.8k total citations · 18 hit papers
518 papers, 39.7k citations indexed

About

Keith T. Flaherty is a scholar working on Molecular Biology, Oncology and Pulmonary and Respiratory Medicine. According to data from OpenAlex, Keith T. Flaherty has authored 518 papers receiving a total of 39.7k indexed citations (citations by other indexed papers that have themselves been cited), including 363 papers in Molecular Biology, 310 papers in Oncology and 109 papers in Pulmonary and Respiratory Medicine. Recurrent topics in Keith T. Flaherty's work include Melanoma and MAPK Pathways (277 papers), Cutaneous Melanoma Detection and Management (86 papers) and CAR-T cell therapy research (75 papers). Keith T. Flaherty is often cited by papers focused on Melanoma and MAPK Pathways (277 papers), Cutaneous Melanoma Detection and Management (86 papers) and CAR-T cell therapy research (75 papers). Keith T. Flaherty collaborates with scholars based in United States, Australia and Germany. Keith T. Flaherty's co-authors include Antoni Ribas, Peter J. O’Dwyer, Ryan J. Sullivan, Grant A. McArthur, Georgina V. Long, Paul B. Chapman, David E. Fisher, Jennifer A. Wargo, Russell W. Jenkins and David A. Barbie and has published in prestigious journals such as Nature, New England Journal of Medicine and Proceedings of the National Academy of Sciences.

In The Last Decade

Keith T. Flaherty

498 papers receiving 39.1k citations

Hit Papers

Final Version of 2009 AJCC Melanoma Staging and Classific... 2006 2026 2012 2019 2009 2010 2017 2012 2012 1000 2.0k 3.0k
What are hit papers?

Hit papers significantly outperform the citation benchmark for their cohort. A paper qualifies if it has ≥500 total citations, achieves ≥1.5× the top-1% citation threshold for papers in the same subfield and year (this is the minimum needed to enter the top 1%, not the average within it), or reaches the top citation threshold in at least one of its specific research topics.

  1. Final Version of 2009 AJCC Melanoma Staging and Classification
    2009 3.3k citations Charles M. Balch, Jeffrey E. Gershenwald et al. Journal of Clinical Oncology profile →
  2. Inhibition of Mutated, Activated BRAF in Metastatic Melanoma
    2010 2.6k citations Keith T. Flaherty, Peter J. O’Dwyer et al. profile →
  3. Melanoma staging: Evidence‐based changes in the American Joint Committee on Cancer eighth edition cancer staging manual
    2017 1.4k citations Jeffrey E. Gershenwald, Vernon K. Sondak et al. profile →
  4. Tumour micro-environment elicits innate resistance to RAF inhibitors through HGF secretion
    2012 1.4k citations Ravid Straussman, Michal Barzily-Rokni et al. profile →
  5. Improved survival with MEK Inhibition in BRAF-mutated melanoma for the METRIC Study Group
    2012 1.1k citations Keith T. Flaherty, Claus Garbe et al. profile →
  6. Mechanisms of resistance to immune checkpoint inhibitors
    2018 999 citations Keith T. Flaherty et al. profile →
  7. Targeted agents and immunotherapies: optimizing outcomes in melanoma
    2017 869 citations Keith T. Flaherty et al. profile →
  8. Phase II Placebo-Controlled Randomized Discontinuation Trial of Sorafenib in Patients With Metastatic Renal Cell Carcinoma
    2006 794 citations Mark J. Ratain, Tim Eisen et al. Journal of Clinical Oncology profile →
  9. EGFR-Mediated Reactivation of MAPK Signaling Contributes to Insensitivity of BRAF -Mutant Colorectal Cancers to RAF Inhibition with Vemurafenib
    2012 767 citations Ryan B. Corcoran, Hiromichi Ebi et al. Cancer Discovery profile →
  10. Encorafenib plus binimetinib versus vemurafenib or encorafenib in patients with BRAF-mutant melanoma (COLUMBUS): a multicentre, open-label, randomised phase 3 trial
    2018 675 citations Claus Garbe, Dirk Schadendorf et al. profile →
  11. Selective BRAFV600E Inhibition Enhances T-Cell Recognition of Melanoma without Affecting Lymphocyte Function
    2010 574 citations Alexandria P. Cogdill, Keith T. Flaherty et al. Cancer Research profile →
  12. Phase II Trial of Sorafenib in Advanced Thyroid Cancer
    2008 535 citations Vandana G. Abramson, Andrea B. Troxel et al. Journal of Clinical Oncology profile →
  13. Dabrafenib plus trametinib in patients with BRAFV600-mutant melanoma brain metastases (COMBI-MB): a multicentre, multicohort, open-label, phase 2 trial
    2017 482 citations Keith T. Flaherty et al. profile →
  14. Robust prediction of response to immune checkpoint blockade therapy in metastatic melanoma
    2018 456 citations Dennie T. Frederick, Keith T. Flaherty et al. profile →
  15. Safety, pharmacokinetic, pharmacodynamic, and efficacy data for the oral MEK inhibitor trametinib: a phase 1 dose-escalation trial
    2012 424 citations Razelle Kurzrock, Keith T. Flaherty et al. profile →
  16. Overall survival in patients with BRAF-mutant melanoma receiving encorafenib plus binimetinib versus vemurafenib or encorafenib (COLUMBUS): a multicentre, open-label, randomised, phase 3 trial
    2018 392 citations Claus Garbe, Dirk Schadendorf et al. profile →
  17. A Melanoma Cell State Distinction Influences Sensitivity to MAPK Pathway Inhibitors
    2014 357 citations David J. Konieczkowski, Cory M. Johannessen et al. Cancer Discovery profile →
  18. High‐dose glucocorticoids for the treatment of ipilimumab‐induced hypophysitis is associated with reduced survival in patients with melanoma
    2018 348 citations Donald P. Lawrence, Keith T. Flaherty et al. profile →

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name h Career Trend Papers Cites
Keith T. Flaherty United States 92 24.8k 23.3k 7.1k 6.3k 5.7k 518 39.7k
Georgina V. Long Australia 85 25.4k 1.0× 16.6k 0.7× 9.2k 1.3× 5.2k 0.8× 3.5k 0.6× 684 34.4k
Antoni Ribas United States 110 39.7k 1.6× 27.4k 1.2× 22.6k 3.2× 7.5k 1.2× 6.3k 1.1× 551 61.0k
Jeffrey A. Sosman United States 73 16.2k 0.7× 15.5k 0.7× 6.9k 1.0× 8.3k 1.3× 5.0k 0.9× 347 28.5k
Neal Rosen United States 100 12.2k 0.5× 24.7k 1.1× 3.0k 0.4× 5.7k 0.9× 4.2k 0.7× 255 34.8k
Grant A. McArthur Australia 74 15.0k 0.6× 15.2k 0.7× 3.8k 0.5× 5.4k 0.9× 3.1k 0.5× 395 26.8k
Reinhard Dummer Switzerland 100 22.4k 0.9× 19.1k 0.8× 14.7k 2.1× 3.4k 0.5× 2.8k 0.5× 951 44.0k
Richard A. Scolyer Australia 84 21.3k 0.9× 13.3k 0.6× 6.6k 0.9× 3.8k 0.6× 4.3k 0.8× 707 30.6k
Brian Druker United States 106 10.9k 0.4× 17.1k 0.7× 5.8k 0.8× 6.3k 1.0× 3.2k 0.6× 607 54.8k
David B. Solit United States 82 10.6k 0.4× 15.6k 0.7× 2.4k 0.3× 5.6k 0.9× 4.8k 0.8× 365 26.2k
Paolo A. Ascierto Italy 75 18.1k 0.7× 11.4k 0.5× 7.1k 1.0× 3.5k 0.6× 2.5k 0.4× 757 25.2k

Countries citing papers authored by Keith T. Flaherty

Since Specialization
Citations

This map shows the geographic impact of Keith T. Flaherty's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Keith T. Flaherty with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Keith T. Flaherty more than expected).

Fields of papers citing papers by Keith T. Flaherty

Since Specialization
Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Keith T. Flaherty. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Keith T. Flaherty. The network helps show where Keith T. Flaherty may publish in the future.

Co-authorship network of co-authors of Keith T. Flaherty

This figure shows the co-authorship network connecting the top 25 collaborators of Keith T. Flaherty. A scholar is included among the top collaborators of Keith T. Flaherty based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Keith T. Flaherty. Keith T. Flaherty is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

20 of 20 papers shown
1.
Caksa, Signe, Nicole A. Wilski, Inna Chervoneva, et al.. (2023). Targeting Upregulated cIAP2 in SOX10-Deficient Drug Tolerant Melanoma. Molecular Cancer Therapeutics. 22(9). 1087–1099. 8 indexed citations
2.
Anderson, Kenneth C., Lewis C. Cantley, Riccardo Dalla‐Favera, et al.. (2022). The AACR Journals: Advancing Progress Toward the AACR's 115-Year Mission. Cancer Discovery. 12(11). 2475–2481.
3.
Xu, Wenxin, Mäneka Puligandla, Brian Halbert, et al.. (2021). Plasma KIM-1 Is Associated with Recurrence Risk after Nephrectomy for Localized Renal Cell Carcinoma: A Trial of the ECOG-ACRIN Research Group (E2805). Clinical Cancer Research. 27(12). 3397–3403. 26 indexed citations
4.
Xu, Wenxin, Mäneka Puligandla, Judith Manola, et al.. (2019). Angiogenic Factor and Cytokine Analysis among Patients Treated with Adjuvant VEGFR TKIs in Resected Renal Cell Carcinoma. Clinical Cancer Research. 25(20). 6098–6106. 11 indexed citations
5.
Jilaveanu, Lucia B., Mäneka Puligandla, Sarah A. Weiss, et al.. (2017). Tumor Microvessel Density as a Prognostic Marker in High-Risk Renal Cell Carcinoma Patients Treated on ECOG-ACRIN E2805. Clinical Cancer Research. 24(1). 217–223. 24 indexed citations
6.
Friedman, Adam A., Yun Xia, Lorenzo Trippa, et al.. (2017). Feasibility of Ultra-High-Throughput Functional Screening of Melanoma Biopsies for Discovery of Novel Cancer Drug Combinations. Clinical Cancer Research. 23(16). 4680–4692. 5 indexed citations
7.
Jonas, Oliver, Madeleine J. Oudin, Tatsiana Kosciuk, et al.. (2016). Parallel In Vivo Assessment of Drug Phenotypes at Various Time Points during Systemic BRAF Inhibition Reveals Tumor Adaptation and Altered Treatment Vulnerabilities. Clinical Cancer Research. 22(24). 6031–6038. 18 indexed citations
8.
Kato, Shumei, Scott M. Lippman, Keith T. Flaherty, & Razelle Kurzrock. (2016). The Conundrum of Genetic “Drivers” in Benign Conditions. JNCI Journal of the National Cancer Institute. 108(8). djw036–djw036. 102 indexed citations
9.
Konieczkowski, David J., Cory M. Johannessen, Omar O. Abudayyeh, et al.. (2014). A Melanoma Cell State Distinction Influences Sensitivity to MAPK Pathway Inhibitors. Cancer Discovery. 4(7). 816–827. 357 indexed citations breakdown →
10.
Corcoran, Ryan B., S. Michael Rothenberg, Aaron N. Hata, et al.. (2013). TORC1 Suppression Predicts Responsiveness to RAF and MEK Inhibition in BRAF- Mutant Melanoma. Science Translational Medicine. 5(196). 196ra98–196ra98. 110 indexed citations
11.
Maertens, Ophélia, Bryan W. Johnson, Pablo E. Hollstein, et al.. (2012). Elucidating Distinct Roles for NF1 in Melanomagenesis. Cancer Discovery. 3(3). 338–349. 184 indexed citations
12.
Corcoran, Ryan B., Hiromichi Ebi, Alexa B. Turke, et al.. (2012). EGFR-Mediated Reactivation of MAPK Signaling Contributes to Insensitivity of BRAF -Mutant Colorectal Cancers to RAF Inhibition with Vemurafenib. Cancer Discovery. 2(3). 227–235. 767 indexed citations breakdown →
13.
Si, Lu, Yanyan Zhu, Xiaowei Xu, et al.. (2011). Large-Scale Analysis of KIT Aberrations in Chinese Patients with Melanoma. Clinical Cancer Research. 17(7). 1684–1691. 181 indexed citations
14.
Niessner, Heike, Daniela Beck, Tobias Sinnberg, et al.. (2010). The Farnesyl Transferase Inhibitor Lonafarnib Inhibits mTOR Signaling and Enforces Sorafenib-Induced Apoptosis in Melanoma Cells. Journal of Investigative Dermatology. 131(2). 468–479. 50 indexed citations
15.
Balch, Charles M., Jeffrey E. Gershenwald, Seng-Jaw Soong, et al.. (2009). Final Version of 2009 AJCC Melanoma Staging and Classification. Journal of Clinical Oncology. 27(36). 6199–6206. 3342 indexed citations breakdown →
16.
Abramson, Vandana G., Andrea B. Troxel, Anoma Nellore, et al.. (2008). Phase II Trial of Sorafenib in Advanced Thyroid Cancer. Journal of Clinical Oncology. 26(29). 4714–4719. 535 indexed citations breakdown →
17.
Smalley, Keiran S.M., Mercedes Lioni, Maurizia Dalla Palma, et al.. (2008). Increased cyclin D1 expression can mediate BRAF inhibitor resistance in BRAF V600E–mutated melanomas. Molecular Cancer Therapeutics. 7(9). 2876–2883. 244 indexed citations
18.
Smalley, Keiran S.M., Rooha Contractor, Thiennga K. Nguyen, et al.. (2008). Identification of a Novel Subgroup of Melanomas with KIT/Cyclin-Dependent Kinase-4 Overexpression. Cancer Research. 68(14). 5743–5752. 82 indexed citations
19.
Ratain, Mark J., Tim Eisen, Walter M. Stadler, et al.. (2006). Phase II Placebo-Controlled Randomized Discontinuation Trial of Sorafenib in Patients With Metastatic Renal Cell Carcinoma. Journal of Clinical Oncology. 24(16). 2505–2512. 794 indexed citations breakdown →
20.
Smalley, Keiran S.M., Nikolas K. Haass, Patricia Brafford, et al.. (2006). Multiple signaling pathways must be targeted to overcome drug resistance in cell lines derived from melanoma metastases. Molecular Cancer Therapeutics. 5(5). 1136–1144. 370 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact

Breakdown of academic impact, for papers by Georgina V. Long Breakdown of academic impact, for papers by Antoni Ribas Breakdown of academic impact, for papers by Jeffrey A. Sosman Breakdown of academic impact, for papers by Neal Rosen Breakdown of academic impact, for papers by Grant A. McArthur Breakdown of academic impact, for papers by Reinhard Dummer Breakdown of academic impact, for papers by Richard A. Scolyer Breakdown of academic impact, for papers by Brian Druker Breakdown of academic impact, for papers by David B. Solit Breakdown of academic impact, for papers by Paolo A. Ascierto
Rankless by CCL
2026